ClinicalTrials.gg
Not yet recruitingNCT07947173Updated Nov 18, 2026

Phase 1 Trial to Assess Safety and Immunogenicity of Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105)

A Phase 1 interventional study of JCXH-105 and Placebo in Herpes Zoster (HZ), sponsored by Immorna Biotherapeutics, Inc.. Not yet recruiting. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Immorna Biotherapeutics, Inc. · Phase 1, Interventional, and Prevention

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Study summary

Herpes zoster is caused by reactivation of varicella zoster virus. This is a Phase 1 clinical trial to evaluate the safety and immunogenicity of self-replicating RNA (srRNA) herpes zoster vaccine JCXH-105. Eligible participants will receive 2 doses of study vaccine/placebo at planned dose levels and follow scheduled safety and immunogenicity follow-up visits. The goal of this study is to assess the safety profile and immune response induced by JCXH-105.

02

Conditions studied

  • Herpes Zoster (HZ)

Browse trials for

03

In context

Herpes Zoster

300 studies on the registry are indexed under Herpes Zoster; 56 are open to participants now.

This study's planned enrollment of 72 is below the median of 160 across 248 interventional studies indexed under Herpes Zoster.

Browse Herpes Zoster studies →

Lead sponsor

Immorna Biotherapeutics, Inc. is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (1) Gender: Male or female; (2) Age: ≥ 40 years of age at screening. (3) Status: Healthy participants. (4) Subject agrees not to receive any other herpes zoster vaccine while participating in this study.

    (5) All Laboratory values required for screening prior to study enrollment are within normal limits or abnormal without clinical significance as judged by the investigator.

    (6) Female participants must meet the following criteria:

    • Surgically sterile or for ≥ 2 years, or women of (premenopausal or postmenopausal for \< 2 years) who have a negative pregnancy test and are willing to use effective from the first administration of vaccine/placebo to 12 months after the full-course vaccination.
    • Agree not to breastfeed from the first administration of investigational vaccine/placebo to at least 3 months after the full-course vaccination.

      (7) Male participants should meet the following criteria: agree to use effective contraception and not to donate sperms from the first administration of investigational vaccine/placebo to 12 months after the full-course vaccination.

      (8) Able to fully understand and voluntarily sign the form.

Exclusion criteria

Exclusion Criteria:

  • (1) Participants who have a history of herpes zoster or are currently diagnosed with herpes zoster, or have a history of chickenpox, or a history of close contact with chickenpox/herpes zoster patients within 30 days before enrollment.

    (2) History of chickenpox or herpes zoster vaccination. (3) to any component of the vaccine/placebo, or any previous serious reaction to vaccination, or a history of serious allergic disease.

    (4) Fever within 3 days prior to enrollment, acute illness or acute exacerbation of chronic illness within 7 days prior to enrollment, or taking antipyretic, analgesic, and anti-allergic drugs within 3 days prior to enrollment.

    (5) History of significant cardiac disease, or myocarditis or pericarditis. (6) At present, participants with severe liver and kidney diseases, spleen dysfunction or asplenia, hypertension that cannot be controlled by drugs, diabetes with serious complications and other chronic diseases are currently suffering.

    (7) Use of whole blood, blood products, or immunoglobulins within 3 months prior to vaccination or planned use during the study.

    (8) Has received any inactive vaccine within 14 days prior to the first dose of vaccine.

    (9) Received the following within 28 days prior to the first dose of vaccine: Any live/mRNA vaccine; Immunomodulators or drugs; Granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor; Receiving systemic for 3 or more consecutive days. (Note: Study participants are permitted to receive long-term systemic prednisone at a dose ≤10 mg/day, or systemic corticosteroids equivalent to prednisone. Topical medications such as ointments, eye drops, inhalants or nasal sprays are allowed, provided that the topical medications should not exceed the recommended dose in the instructions and there are no signs of systemic exposure.) (10) Have confirmed or suspected immunosuppression, immunodeficiency, or disease.

    (11) Positive screening test for antibodies, surface antigen (HBsAg), virus (HCV) antibodies.

    (12) Known history of active or latent tuberculosis (Mycobacterium tuberculosis).

    (13) Axillary temperature > 37.0 °C at enrollment. (14) Participation in another drug, device, or other vaccine clinical trial within 30 days prior to the first dose of investigational vaccine/placebo or planned participation during the study period.

    (15) Participants with dermatologic condition that could affect local solicited adverse reaction assessments (e.g., tattoos, psoriasis, patches affecting skin over the deltoid area).

    (16) Participants with to IM injection. (17) The investigator considers that there are other situations unsuitable for participating in this study, including but not limited to failure to participate in follow-up according to the study protocol.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Low-dose JCXH-105

    Participants receive low dose of JCXH-105

    Biological: JCXH-105

  • Placebo comparator
    Low-dose placebo

    Participants receive low dose of placebo

    Drug: Placebo

  • Experimental
    Medium-dose JCXH-105

    Participants receive medium dose of JCXH-105

    Biological: JCXH-105

  • Placebo comparator
    Medium-dose placebo

    Participants receive medium dose of placebo

    Drug: Placebo

  • Experimental
    High-dose JCXH-105

    Participants receive high dose of JCXH-105

    Biological: JCXH-105

  • Placebo comparator
    High-dose placebo

    Participants receive high dose of placebo

    Drug: Placebo

Interventions

  • BiologicalJCXH-105

    Self-replicating RNA (srRNA) Herpes Zoster Vaccine (JCXH-105)

  • DrugPlacebo

    Placebo (sodium chloride injection) as control

06

What researchers measure

Primary outcomes

  1. Serious adverse events (SAEs)

    Including frequency, severity, duration, and relationship to the investigational vaccine/placebo

    Time frame: From Day 1 post- administration through 360 days after the full-course vaccination

  2. Solicited local injection site adverse events

    Including frequency, severity, duration, and relationship to the investigational vaccine/placebo

    Time frame: Within 14 days after each dose of investigational vaccine/placebo

  3. Solicited systemic adverse events

    Including frequency, severity, duration, and relationship to the investigational vaccine/placebo

    Time frame: Within 14 days after each dose of the investigational vaccine/placebo

  4. Unsolicited AEs

    Including frequency, severity, duration, and relationship to the investigational vaccine/placebo

    Time frame: Within 30 days after each dose of the investigational vaccine/placebo

  5. Laboratory parameters

    Clinically significant abnormal changes of laboratory parameters compared with pre-vaccination

    Time frame: On the third day after each dose of the investigational vaccine/placebo

  6. Adverse events of special interest (AESIs)

    Including frequency, severity, duration, and relationship to the investigational vaccine/placebo

    Time frame: From Day 1 post administration through 360 days after the full-course vaccination

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Mar 2028, 16 months later.

Of 21 phase 1 interventional studies under Herpes Zoster, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's planned 16 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartEst.
Nov 2026
Primary completionEst.
Mar 2028
CompletionEst.
Mar 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07947173
Lead sponsor
Immorna Biotherapeutics, Inc.
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Nov 2026 (estimated)
Primary completion
Mar 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
Nov 18, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JCXH-105

Start the discussion